Dateline City:
KENILWORTH, N.J.
Data from Pivotal KEYNOTE-087 Trial Show Overall Response Rate (ORR) of 69.0 Percent and Complete Remission Rate (CRR) of 22.4 Percent
With More than Two Years of Follow-up, Findings from KEYNOTE-013 Show ORR of 58 Percent and CRR of 19 Percent with Responses of 12 Months or Greater in 70 Percent of Responding Patients
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today updated findings evaluating KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, in two trials of
patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
In the KEYNOTE-087 and KEYNOTE-013 trials, KEYTRUDA demonstrated overall
response rates (ORR) of 69.0 percent and 58 percent, respectively.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
@Merck
read more